Allogene Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-190.89	-257.59	-327.27	-340.41	-182.05
Depreciation & Amortization	12.36	13.64	14.2	14.3	10.45
Stock-Based Compensation	37.64	51.74	65.95	83.6	80.82
Other Adjustments	2.52	16.71	30.69	18.1	-62.08
Changes in Accounts Payable	-1.23	-0.5	-7.5	4.87	-0.77
Changes in Accrued Expenses	-2.52	-1.26	-6.82	1.75	3.65
Changes in Unearned Revenue	-	-	-	-0.02	-38.3
Changes in Other Operating Activities	-7.13	-23.03	-6.98	-2.7	3.46
Operating Cash Flow	-149.25	-200.3	-237.73	-220.52	-184.81
Capital Expenditures	-0.39	-0.69	-1.52	-5.19	-21.45
Purchases of Investments	-138.26	-361.48	-438.63	-248.11	-525.58
Proceeds from Sale of Investments	234.2	437.86	603.43	359.46	728.39
Other Investing Activities	-	-	-	-	-17.71
Investing Cash Flow	95.56	75.69	163.29	106.16	163.66
Issuance of Common Stock	23.25	114.4	95.7	2.95	11.96
Net Common Stock Issued (Repurchased)	23.25	114.4	95.7	2.95	11.96
Other Financing Activities	6.91	2.28	-	-	-
Financing Cash Flow	30.16	116.68	95.7	2.95	11.96
Net Cash Flow	-23.53	-7.94	21.25	-111.41	-9.19
Free Cash Flow	-149.63	-200.99	-239.25	-225.71	-206.26
FCF Margin	-	-913609.09%	-251841.05%	-144685.90%	-180.79%
Free Cash Flow Per Share	-0.68	-1.03	-1.52	-1.58	-1.52
Levered Free Cash Flow	-189.79	-269.44	-335.89	-327.41	-224.99
Unlevered Free Cash Flow	-208.22	-284.58	-336.36	-322.54	-223.13

Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q